Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-64657

Galanis, E; Wu, W; Cloughesy, T; Lamborn, K; Mann, B; Wen, P Y; Reardon, D A; Wick, W; Macdonald, D; Armstrong, T S; Weller, M; Vogelbaum, M; Colman, H; Sargent, D J; van den Bent, M J; Gilbert, M; Chang, S (2012). Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncology, 13(5):e196-e204.

[img] PDF - Registered users only
245kB

Abstract

Advances in the management of gliomas, including the approval of agents such as temozolomide and bevacizumab, have created an evolving therapeutic landscape in glioma treatment, thus affecting our ability to reliably use historical controls to comparatively assess the activity of new therapies. Furthermore, the increasing availability of novel, targeted agents--which are competing for a small patient population, in view of the low incidence of primary brain tumours--draws attention to the need to improve the efficiency of phase 2 clinical testing in neuro-oncology to expeditiously transition the most promising of these drugs or combinations to potentially practice-changing phase 3 trials. In this report from the Response Assessment in Neurooncology (RANO) group, we review phase 2 trial designs that can address these challenges and capitalise on scientific and clinical advances in brain tumour treatment in neuro-oncology to accelerate and optimise the selection of drugs deserving further testing in phase 3 trials. Although there is still a small role for single-arm and non-comparative phase 2 designs, emphasis is placed on the potential role that comparative randomised phase 2 designs--such as screening designs, selection designs, discontinuation designs, and adaptive designs, including seamless phase 2/3 designs--can have. The rational incorporation of these designs, as determined by the specific clinical setting and the trial's endpoints or goals, has the potential to substantially advance new drug development in neuro-oncology.

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
DDC:610 Medicine & health
Language:English
Date:2012
Deposited On:18 Sep 2012 12:15
Last Modified:18 Jan 2013 10:32
Publisher:Elsevier
ISSN:1470-2045
Publisher DOI:10.1016/S1470-2045(11)70406-5
PubMed ID:22554547
Citations:Google Scholar™
Scopus®. Citation Count: 10

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page